LV10057B - Contrast media and process of preparation and use of it - Google Patents

Contrast media and process of preparation and use of it Download PDF

Info

Publication number: LV10057B
Authority: LV; Latvia
Prior art keywords: contrast agent; contrast; oxygen; oxygenation; kpa
Prior art date: 1989-09-04

Application number

LVP-92-584A

Other languages

English (en)

Latvian (lv)

Other versions

LV10057A (lv

Inventor

Torsten Almen

Lars Baath

Audun Nesheim Oksendal

Original Assignee

Nycomed Imaging As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-04

Filing date

1992-12-30

Publication date

1994-10-20

1992-12-30 Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As

1994-05-10 Publication of LV10057A publication Critical patent/LV10057A/xx

1994-10-20 Publication of LV10057B publication Critical patent/LV10057B/lv

Links

239000002872 contrast media Substances 0.000 title claims abstract description 122
238000000034 method Methods 0.000 title claims description 12
238000002360 preparation method Methods 0.000 title claims description 3
229940039231 contrast media Drugs 0.000 title abstract description 15
239000001301 oxygen Substances 0.000 claims description 41
229910052760 oxygen Inorganic materials 0.000 claims description 41
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 40
238000006213 oxygenation reaction Methods 0.000 claims description 31
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 9
239000007789 gas Substances 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
229960000554 metrizamide Drugs 0.000 claims description 7
BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
241001465754 Metazoa Species 0.000 claims description 5
229960001025 iohexol Drugs 0.000 claims description 3
NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 3
229960004647 iopamidol Drugs 0.000 claims description 3
XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims description 3
229910001415 sodium ion Inorganic materials 0.000 claims description 3
AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 claims description 2
229960004537 ioversol Drugs 0.000 claims description 2
239000011347 resin Substances 0.000 claims 1
229920005989 resin Polymers 0.000 claims 1
208000003663 ventricular fibrillation Diseases 0.000 abstract description 6
230000000747 cardiac effect Effects 0.000 abstract description 4
238000002583 angiography Methods 0.000 abstract description 3
230000001706 oxygenating effect Effects 0.000 abstract 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 36
239000000126 substance Substances 0.000 description 31
210000002216 heart Anatomy 0.000 description 24
239000011734 sodium Substances 0.000 description 21
230000009467 reduction Effects 0.000 description 19
239000011780 sodium chloride Substances 0.000 description 18
239000000243 solution Substances 0.000 description 17
241000283973 Oryctolagus cuniculus Species 0.000 description 14
230000000694 effects Effects 0.000 description 14
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 13
229910052708 sodium Inorganic materials 0.000 description 13
238000012360 testing method Methods 0.000 description 13
230000036772 blood pressure Effects 0.000 description 12
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 10
230000010412 perfusion Effects 0.000 description 10
229910052740 iodine Inorganic materials 0.000 description 9
239000011630 iodine Substances 0.000 description 9
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
150000002500 ions Chemical class 0.000 description 6
239000000047 product Substances 0.000 description 6
239000000654 additive Substances 0.000 description 5
230000006872 improvement Effects 0.000 description 5
229910002092 carbon dioxide Inorganic materials 0.000 description 4
239000001569 carbon dioxide Substances 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
230000004217 heart function Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
229960004359 iodixanol Drugs 0.000 description 4
NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 4
230000003204 osmotic effect Effects 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000007787 solid Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
210000000709 aorta Anatomy 0.000 description 3
206010003119 arrhythmia Diseases 0.000 description 3
230000006793 arrhythmia Effects 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000011521 glass Substances 0.000 description 3
210000004165 myocardium Anatomy 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
239000004033 plastic Substances 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
238000002604 ultrasonography Methods 0.000 description 3
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
238000009530 blood pressure measurement Methods 0.000 description 2
238000009534 blood test Methods 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
229910001424 calcium ion Inorganic materials 0.000 description 2
230000022900 cardiac muscle contraction Effects 0.000 description 2
229920001971 elastomer Polymers 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
230000004118 muscle contraction Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
210000001147 pulmonary artery Anatomy 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
RHISTIGVAKTTCM-UHFFFAOYSA-N 5-[[3-[3,5-bis(1,3-dihydroxypropan-2-ylcarbamoyl)-n-(2-hydroxyethyl)-2,4,6-triiodoanilino]-3-oxopropanoyl]-(2-hydroxyethyl)amino]-1-n,3-n-bis(1,3-dihydroxypropan-2-yl)-2,4,6-triiodobenzene-1,3-dicarboxamide Chemical compound IC=1C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C(I)C=1N(CCO)C(=O)CC(=O)N(CCO)C1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I RHISTIGVAKTTCM-UHFFFAOYSA-N 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
241001077673 Mylon Species 0.000 description 1
102000004020 Oxygenases Human genes 0.000 description 1
108090000417 Oxygenases Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000219289 Silene Species 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical class [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000007321 biological mechanism Effects 0.000 description 1
230000004397 blinking Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
-1 chlorine ions Chemical class 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000000039 congener Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000002586 coronary angiography Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
229960005423 diatrizoate Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
231100000226 haematotoxicity Toxicity 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
150000004000 hexols Chemical class 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229960004901 iodamide Drugs 0.000 description 1
VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 description 1
229950002407 iodecimol Drugs 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229960000824 iopentol Drugs 0.000 description 1
IUNJANQVIJDFTQ-UHFFFAOYSA-N iopentol Chemical compound COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I IUNJANQVIJDFTQ-UHFFFAOYSA-N 0.000 description 1
229960002603 iopromide Drugs 0.000 description 1
DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
229940029407 ioxaglate Drugs 0.000 description 1
TYYBFXNZMFNZJT-UHFFFAOYSA-N ioxaglic acid Chemical compound CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC=2C(=C(C(=O)NCCO)C(I)=C(C(O)=O)C=2I)I)=C1I TYYBFXNZMFNZJT-UHFFFAOYSA-N 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
208000012866 low blood pressure Diseases 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229960004712 metrizoic acid Drugs 0.000 description 1
GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
231100000804 nongenotoxic Toxicity 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000012466 permeate Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000013138 pruning Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
229940091252 sodium supplement Drugs 0.000 description 1
239000008279 sol Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Devices For Indicating Variable Information By Combining Individual Elements (AREA)
Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Liquid Crystal (AREA)
Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
Apparatus For Radiation Diagnosis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Compositions Of Macromolecular Compounds (AREA)
Eye Examination Apparatus (AREA)
Magnetic Resonance Imaging Apparatus (AREA)
Radar Systems Or Details Thereof (AREA)
Steroid Compounds (AREA)

LVP-92-584A 1989-09-04 1992-12-30 Contrast media and process of preparation and use of it LV10057B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB898919929A GB8919929D0 (en)	1989-09-04	1989-09-04	Compositions
PCT/EP1990/001481 WO1991003263A1 (en)	1989-09-04	1990-09-01	Contrast media

Publications (2)

Publication Number	Publication Date
LV10057A LV10057A (lv)	1994-05-10
LV10057B true LV10057B (en)	1994-10-20

Family

ID=10662482

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-92-584A LV10057B (en)	1989-09-04	1992-12-30	Contrast media and process of preparation and use of it

Country Status (32)

Country	Link
US (1)	US5447711A (lt)
EP (2)	EP0490917A1 (lt)
JP (1)	JP3049366B2 (lt)
CN (1)	CN1035542C (lt)
AT (1)	ATE101798T1 (lt)
AU (1)	AU633353B2 (lt)
CA (1)	CA2064880A1 (lt)
CZ (1)	CZ281128B6 (lt)
DD (1)	DD297564A5 (lt)
DE (1)	DE69006805T2 (lt)
DK (1)	DK0416698T3 (lt)
EG (1)	EG20035A (lt)
ES (1)	ES2051461T3 (lt)
FI (1)	FI99087C (lt)
GB (1)	GB8919929D0 (lt)
HR (1)	HRP930749A2 (lt)
HU (1)	HU208639B (lt)
IE (1)	IE65527B1 (lt)
IL (1)	IL95565A (lt)
JO (1)	JO1637B1 (lt)
LT (1)	LT3582B (lt)
LV (1)	LV10057B (lt)
MY (1)	MY107103A (lt)
NO (1)	NO920837D0 (lt)
NZ (1)	NZ235171A (lt)
OA (1)	OA09601A (lt)
PT (1)	PT95190B (lt)
RO (1)	RO111023B1 (lt)
RU (1)	RU2106880C1 (lt)
WO (1)	WO1991003263A1 (lt)
YU (1)	YU48072B (lt)
ZA (1)	ZA907034B (lt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5141739A (en) *	1986-07-03	1992-08-25	Advanced Magnetics, Inc.	Delivery of x-ray contrast agents using receptor mediated endocytosis
RU2202276C2 (ru) *	2000-03-06	2003-04-20	Институт хирургии им. А.В. Вишневского РАМН	Способ моделирования оперативного вмешательства на внутренних органах
SE520688C2 (sv) *	2000-04-11	2003-08-12	Bone Support Ab	Ett injicerbart ersättningsmaterial för benmineral
SE517168C2 (sv) *	2000-07-17	2002-04-23	Bone Support Ab	En komposition för ett injicerbart ersättningsmaterial för benmineral
PT1829565E (pt)	2001-12-20	2010-04-26	Bone Support Ab	Novo substituto mineral de osso
SE522098C2 (sv) *	2001-12-20	2004-01-13	Bone Support Ab	Ett nytt benmineralsubstitut
SE0300620D0 (sv) *	2003-03-05	2003-03-05	Bone Support Ab	A new bone substitute composition
US20040175329A1 (en) *	2003-03-07	2004-09-09	Fisher John Steele	Method for continuous visualization of a body lumen
US7803352B2 (en) *	2003-03-07	2010-09-28	John Steele Fisher	Method for continuous visualization of a blood clot or plaque in body lumen
SE0302983D0 (sv) *	2003-11-11	2003-11-11	Bone Support Ab	Anordning för att förse spongiöst ben med benersättnings- och/eller benförstärkningsmaterial och förfarande i samband därmed
SE527528C2 (sv)	2004-06-22	2006-04-04	Bone Support Ab	Anordning för framställning av härdbar massa samt användning av anordningen
RU2268754C1 (ru) *	2004-07-16	2006-01-27	ГОУ ВПО Красноярская государственная медицинская академия Министерства здравоохранения РФ	Способ эндоваскулярного лечения хронического геморроя
US9180137B2 (en)	2010-02-09	2015-11-10	Bone Support Ab	Preparation of bone cement compositions
US9725716B2 (en)	2011-12-06	2017-08-08	Ohio State Innovation Foundation and Research Institute at Nationwide Children's Hospital	Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
DK2958603T3 (en)	2013-02-20	2018-07-16	Bone Support Ab	IMPROVED CURE FOR HARDWARE BONE COMPENSATION
US10610366B2 (en)	2015-01-29	2020-04-07	Theracell, Inc.	Demineralized bone fiber composition for use in minimally invasive surgery
US10639157B2 (en)	2017-03-14	2020-05-05	Theracell, Inc.	Demineralized bone fiber composition for use in minimally invasive surgery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE392100B (sv)	1969-06-27	1977-03-14	Nyegaard & Co As	Trijodbensoylaminer till anvendning sasom rontgenkontrastmedel eller for separation av biologiska material
AR207465A1 (es) *	1974-05-31	1976-10-08	Guerbet Lab Andre	Procedimiento de preparacion de derivados de acido triiodoi2,4,6-(triiodo-2,4,6-benzoil)-amino-alcanoilaminobenzoico de acido triiodo-2,4,6-(triiodo-2,4,6-(triiodo-2,4,6-benzoil)-aminoalcanoilaminobenzoil)-amino-alcanoil-aminobenzoico y de acido triiodo-2,4,6-bis((triiodo-2,4,6-fenil)-carbamoil-metil)-aminoalcanoil-aminobenzoico
CH608189A5 (lt) *	1974-12-13	1978-12-29	Savac Ag
GB1548594A (en)	1976-06-11	1979-07-18	Nyegaard & Co As	Triiodoisophthalic acid amides
JPS55100312A (en) *	1979-01-25	1980-07-31	Toshiro Wada	Contrast medium for blood vessel
BE881234A (fr) *	1980-01-18	1980-05-16	Solarex Corp	Generateur photovoltaique integre et son procede de fabrication
US4341756A (en) *	1980-01-31	1982-07-27	The Regents Of The University Of California	Novel amino-dioxepane intermediates for the synthesis of new non-ionic contrast media
US4396598A (en) *	1982-01-11	1983-08-02	Mallinckrodt, Inc.	Triiodoisophthalamide X-ray contrast agent
DK160868C (da)	1982-11-08	1991-10-14	Nyegaard & Co As	Trijodfenylderivater, fremgangsmaader til fremstilling deraf og radiologisk praeparat indeholdende dem
US4589412A (en) *	1984-01-03	1986-05-20	Intravascular Surgical Instruments, Inc.	Method and apparatus for surgically removing remote deposits
US4865836A (en) *	1986-01-14	1989-09-12	Fluoromed Pharmaceutical, Inc.	Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
EP0231091B1 (en) *	1986-01-24	1993-03-31	Children's Hospital Medical Center	Stable emulsions of highly fluorinated organic compound
GB8906130D0 (en) *	1989-03-17	1989-05-04	Nycomed As	Compositions

1989
- 1989-09-04 GB GB898919929A patent/GB8919929D0/en active Pending
1990
- 1990-09-01 JP JP2512015A patent/JP3049366B2/ja not_active Expired - Lifetime
- 1990-09-01 EP EP90912752A patent/EP0490917A1/en active Pending
- 1990-09-01 HU HU9200734A patent/HU208639B/hu not_active IP Right Cessation
- 1990-09-01 DE DE69006805T patent/DE69006805T2/de not_active Expired - Lifetime
- 1990-09-01 AT AT90202341T patent/ATE101798T1/de active
- 1990-09-01 CA CA002064880A patent/CA2064880A1/en not_active Abandoned
- 1990-09-01 RU SU5011661A patent/RU2106880C1/ru active
- 1990-09-01 RO RO92-200254A patent/RO111023B1/ro unknown
- 1990-09-01 EP EP90202341A patent/EP0416698B1/en not_active Expired - Lifetime
- 1990-09-01 DK DK90202341.5T patent/DK0416698T3/da active
- 1990-09-01 WO PCT/EP1990/001481 patent/WO1991003263A1/en not_active Ceased
- 1990-09-01 AU AU62784/90A patent/AU633353B2/en not_active Ceased
- 1990-09-01 ES ES90202341T patent/ES2051461T3/es not_active Expired - Lifetime
- 1990-09-03 YU YU167790A patent/YU48072B/sh unknown
- 1990-09-03 JO JO19901637A patent/JO1637B1/en active
- 1990-09-03 PT PT95190A patent/PT95190B/pt not_active IP Right Cessation
- 1990-09-03 DD DD90343782A patent/DD297564A5/de not_active IP Right Cessation
- 1990-09-03 IE IE319390A patent/IE65527B1/en not_active IP Right Cessation
- 1990-09-03 IL IL9556590A patent/IL95565A/en not_active IP Right Cessation
- 1990-09-04 MY MYPI90001520A patent/MY107103A/en unknown
- 1990-09-04 CN CN90107463A patent/CN1035542C/zh not_active Expired - Fee Related
- 1990-09-04 CZ CS904300A patent/CZ281128B6/cs unknown
- 1990-09-04 NZ NZ235171A patent/NZ235171A/en unknown
- 1990-09-04 ZA ZA907034A patent/ZA907034B/xx unknown
- 1990-09-04 EG EG9052590A patent/EG20035A/xx active
1992
- 1992-02-28 OA OA60158A patent/OA09601A/en unknown
- 1992-02-28 FI FI920912A patent/FI99087C/fi not_active IP Right Cessation
- 1992-03-03 NO NO920837A patent/NO920837D0/no unknown
- 1992-12-30 LV LVP-92-584A patent/LV10057B/lv unknown
1993
- 1993-04-02 HR HR930749A patent/HRP930749A2/hr not_active Application Discontinuation
- 1993-12-07 LT LTIP1540A patent/LT3582B/lt not_active IP Right Cessation
1994
- 1994-03-14 US US08/213,454 patent/US5447711A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
GB8919929D0 (en)	1989-10-18
LV10057A (lv)	1994-05-10
CN1035542C (zh)	1997-08-06
RU2106880C1 (ru)	1998-03-20
EP0416698A1 (en)	1991-03-13
ATE101798T1 (de)	1994-03-15
CN1051508A (zh)	1991-05-22
PT95190A (pt)	1991-05-22
FI920912A0 (fi)	1992-02-28
PT95190B (pt)	1997-06-30
US5447711A (en)	1995-09-05
WO1991003263A1 (en)	1991-03-21
YU167790A (sh)	1995-03-27
NZ235171A (en)	1992-11-25
HU208639B (en)	1993-12-28
EG20035A (en)	1997-03-27
ES2051461T3 (es)	1994-06-16
AU6278490A (en)	1991-04-08
NO920837L (no)	1992-03-03
JP3049366B2 (ja)	2000-06-05
NO920837D0 (no)	1992-03-03
JPH05500365A (ja)	1993-01-28
OA09601A (en)	1993-04-30
EP0416698B1 (en)	1994-02-23
JO1637B1 (en)	1991-11-27
FI99087C (fi)	1997-10-10
CZ281128B6 (cs)	1996-06-12
LTIP1540A (en)	1995-06-26
RO111023B1 (ro)	1996-06-28
DE69006805D1 (de)	1994-03-31
DK0416698T3 (da)	1994-03-28
HUT60930A (en)	1992-11-30
CZ430090A3 (en)	1996-04-17
IL95565A0 (en)	1991-06-30
DE69006805T2 (de)	1994-06-01
LT3582B (en)	1995-12-27
IE65527B1 (en)	1995-11-01
FI99087B (fi)	1997-06-30
IE903193A1 (en)	1991-03-27
HRP930749A2 (en)	1994-10-31
DD297564A5 (de)	1992-01-16
MY107103A (en)	1995-09-30
ZA907034B (en)	1991-06-26
HU9200734D0 (en)	1992-08-28
AU633353B2 (en)	1993-01-28
IL95565A (en)	1995-01-24
YU48072B (sh)	1997-01-08
EP0490917A1 (en)	1992-06-24
CA2064880A1 (en)	1991-03-05

Publication	Publication Date	Title
LV10057B (en)	1994-10-20	Contrast media and process of preparation and use of it
CA2045610C (en)	1996-03-12	Histidine buffered peritoneal dialysis solution
ES2450131T3 (es)	2014-03-24	Soluciones de diálisis esterilizadas que contienen pirofosfato
Cumming et al.	1971	Unilateral hyperlucent lung syndrome inchildren
NO158328B (no)	1988-05-16	Kontrastmiddel for ultralyd-diagnostikk.
LV10058B (en)	1994-10-20	Contrast media and process of preparation of it
Rude et al.	1982	Effects of intravenous fluorocarbons during and without oxygen enhancement on acute myocardial ischemic injury assessed by measurement of intramyocardial gas tensions
US5366722A (en)	1994-11-22	Contrast media comprising a non-ionic contrast agent and sodium ions
Sanders	1958	Use of a radioactive gas (Kr85) in diagnosis of cardiac shunts.
Martinez et al.	1979	pH homeostasis during cardiopulmonary resuscitation in critically ill patients
McIntosh et al.	1967	The hemodynamic effects of the injection of contrast medium (Isopaque)
ELLIOTT et al.	1989	Role of Fluosol-DA 20% in prehospital resuscitation
Sheps et al.	1980	Depression of intramyocardial oxyhemoglobin dissociation by angiographic contrast media
Berwing et al.	1989	Significance and selection of contrast solution for myocardial contrast echocardiography
Van Voorthuisen	1967	Experiences with Isopaque B in Angiocardiography and Abdominal Angiography
KAZUE	1995	Effect of low dosage inhaled nitric oxide on pulmonary hypertension in congenital heart disease